Component

Human HbA1c after 16-week rebaudioside A

Context-specific entity; species, compartment and exposure are stated on each claim.

1 recorded relationships. Experimental role, claim status and evidence remain attached to each record.

How nutrients influence it

Every nutrient with a recorded effect on this component, credited to the nutrient that acted rather than the chapter that recorded it. Open a nutrient to see the findings and the conditions they were measured under.

How nutrients reach it in more than one step

Chains of two or more recorded steps that end here, grouped by the nutrient they start from. Each step is a separate finding, so a chain is a route a mechanism could take, not proof that it does.

Tracing routes…

What it does

Every recorded relationship this component is part of, grouped by its role. Plain wording comes first; the technical statement follows.

Recorded relationships

What acts on it

  1. A 16-week trial of 1000 mg/day rebaudioside A in 60 adults versus 62 placebo recipients with type 2 diabetes found no significant difference in HbA1c, fasting glucose, insulin or C-peptide changes.

    Experimental context and source evidence
    evidence_access
    Primary abstract
    experimental_model
    Controlled human intervention; ages 33–75.
    limitations
    This evaluates a particular purified glycoside and regimen, not every possible extract or sugar-replacement strategy.
    nutrient_topic
    Stevia collection; species, compartment, exposure, co-substrates and manipulation remain explicit. · Stevia
    plain_language
    A longer human study did not confirm a general antidiabetic effect.
    primary_references
    Chronic consumption of rebaudioside A, a steviol glycoside, in men and women with type 2 diabetes mellitus. · 2008 · https://pubmed.ncbi.nlm.nih.gov/18555575/ · DOI 10.1016/j.fct.2008.05.007

    Stevia: glycoside metabolism, taste, ion channels and cross-nutrient mechanisms (2026-09-19) · lines 378–384

    AI-assisted research curation; primary references, access levels and experimental limitations individually identified. Not publisher full text. · supports · Controlled human intervention; ages 33–75. · source_derived_draft · unverified_draft

    ## stevia-chronic-reba-null A longer human study did not confirm a general antidiabetic effect. A 16-week trial of 1000 mg/day rebaudioside A in 60 adults versus 62 placebo recipients with type 2 diabetes found no significant difference in HbA1c, fasting glucose, insulin or C-peptide changes. Model: Controlled human intervention; ages 33–75. Limitations: This evaluates a particular purified glycoside and regimen, not every possible extract or sugar-replacement strategy. Evidence access: Primary abstract Chronic consumption of rebaudioside A, a steviol glycoside, in men and women with type 2 diabetes mellitus. · 2008 · https://pubmed.ncbi.nlm.nih.gov/18555575/ · DOI 10.1016/j.fct.2008.05.007
    Complete structured claim and evidence

In the sources

Preserved passages that mention this component, quoted exactly. Open one to read it in context.

    This is a research prototype built from draft material. It is not medical advice, and its statements still await verification against the original studies.

    Evidence, AI assistance and curation standards